期刊文献+

美沙拉嗪与柳氮磺胺吡啶治疗轻中度左半结肠型溃疡性结肠炎的疗效对比观察 被引量:11

The effects of mesalazine and sulfasalazine on mild to moderate left-sided ulcerative colitis
下载PDF
导出
摘要 目的对比观察美沙拉嗪与柳氮磺胺吡啶治疗轻中度溃疡性结肠炎病人的疗效。方法采用随机对照研究方案,将入组的64例溃疡性结肠炎患者随机分为美沙拉嗪治疗组和柳氮磺胺吡啶治疗组,前者服用美沙拉嗪缓释颗粒剂,后者服用柳氮磺胺吡啶,疗程均为6周。记录治疗过程中出现的不良事件,根据改良Mayo评分系统评估两组治疗前后评分,判断治疗效果。结果美沙拉嗪治疗组有效率为90.6%,柳氮磺胺吡啶治疗组有效率为70.0%,两组有显著性差异(P<0.05);美沙拉嗪治疗组不良事件发生率显著低于柳氮磺胺吡啶治疗组。结论美沙拉嗪治疗轻中度左半结肠型溃疡性结肠炎疗效显著而又安全。 Objective To compare the effects of mesalazine and sulfasalazine for ulcerative colitis pa-tients. Methods patients with ulcerative colitis were randomly divided into treatment group and control group. Treatment group received mesalazine, and control group received sulfasalazine for a course of 6 weeks. The efficacy and adverse events of the two groups were observed. Results The total effective rate was 89.7.0%in treatment group which was significantly higher than 77.8%in control group (P〈0.05). Adverse reaction rate was 5.1%in treatment group which was lower than 9.7%in control group, but the difference was not statisti-cally significant (P〉0.05). Conclusion Sulfasalazine is effective in treatment of ulcerative colitis.
出处 《现代消化及介入诊疗》 2014年第4期238-240,共3页 Modern Interventional Diagnosis and Treatment in Gastroenterology
关键词 美沙拉嗪 柳氮磺胺吡啶 溃疡性结肠炎 疗效 Mesalazine Sulfasalazine Ulcerative colitis Efficacy
  • 相关文献

参考文献9

  • 1Staerk Laursen L1, Stokholm M, Bukhave K, et al. Disposition of 5- aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion. Gut, 1990,31(11): 1271-1276.
  • 2Ardizzone S, Dolodo P, Ranzi T, et al. Mesalazine foam (salofalk foam) in the treatment of active distal ulcerative colitis: a compara- tive trial vs Salofalk enema. The SAF23 study group. Ital J Gas- troenterol Hepatol, 1999,31(8):677-684.
  • 3Gisbert JP, Gomollon F, Mate J, et al. Role of 5-aminosalicylic acid (5-ASA) in treatment of inflammatory bowel disease: a systematic review. Dig Dis Sci, 2002,47(3):471-488.
  • 4炎症性肠病诊断与治疗的共识意见(2012年·广州)[J].胃肠病学,2012,17(12):763-781. 被引量:541
  • 5Sandbom WJ, Hanauer SB. Systematic review: the pharmacoki-net- ic profiles of oral mesalazine formulations and mesalazine pro- drugs used in the management of ulcerative colitis. Aliment Pharmacol Ther, 200337(1):29-42.
  • 6Friend DR. New oral delivery systems for treatment ofinflarnma- tory bowel disease. Adv Drug Deliv Rev, 2005,57(2):247-265.
  • 7Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet, 2007,369 (9573): 164,1-1657.
  • 8Christensen LA. 5-Aminosalicylic acid containing drugs. Delivery, fate, and possible clinical implications in man. Dan Med Bull, 2000, 47(1):20-41.
  • 9Wadworth AN, Fitton AN. Olsalazine. A review of its pharmacody - namic and pharmacokinetic properties, and therapeutic potential inin-flammatory bowel disease. Drugs, 1991, 41(4):647 -664.

二级参考文献13

共引文献540

同被引文献126

引证文献11

二级引证文献57

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部